Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer
European Urology Focus · 2024
DOI: 10.1016/j.euf.2024.03.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Ursula M Vogl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland. Electronic address: ursula.vogl@eoc.ch. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cisplatin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland. Electronic address: ursula.vogl@eoc.ch.
- Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland; Medical Oncology Unit, University Hospital Parma, Parma, Italy.
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University Vienna, Austria.
Zitieren
APA
Vogl, U. M., Testi, I., & De Santis, M. (2024). Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2024.03.005
Vancouver
Vogl UM, Testi I, De Santis M. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer. European Urology Focus. 2024. doi:10.1016/j.euf.2024.03.005
BibTeX
@article{Vogl2024,
author = {Vogl, Ursula M and Testi, Irene and De Santis, Maria},
title = {Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2024.03.005}
}
EUVIMED